Skip to main content
SpringerLink
Log in

Hemmstoffe des Renin-Angiotensin-Systems

  • Chapter
Arzneiverordnungs-Report 2010

  • 686 Accesses

Zusammenfassung

ACE-Hemmer, Angiotensinrezeptorantagonisten und Renininhibitoren sind Hemmstoffe des Renin-Angiotensin-Aldosteron-Systems. Wichtigster Mediator dieses Systems ist Angiotensin II, das über Kurz-und Langzeiteffekte maßgeblich an der Blutdruckregulation beteiligt ist. Angiotensin II ist einer der stärksten direkten Vasokonstriktoren und steigert dadurch den Blutdruck. Zusätzlich hat es zahlreiche indirekte Gefäßeffekte, da es die Freisetzung von Noradrenalin, die adrenale Aldosteronsynthese, die tubuläre Natriumrückresorption und die Bildung von Wachstumsfaktoren (Herzhypertrophie, Remodeling) erhöht. Alle diese Angiotensinwirkungen werden über AT1-Rezeptoren vermittelt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Anlauf M (2006): Beurteilung von Therapien mit der “number needed to treat“. Deutsches Ärzteblatt 103: A3254–3258.

    Google Scholar 

  • Arzneimittelkommission der Deutschen Ärzteschaft (2004): Empfehlungen zur Therapie der arteriellen Hypertonie. 2. Auflage, Arzneiverordnung in der Praxis, Band 31, Sonderheft 2 (Therapieempfehlungen), Internet: www.akdae.de/35/74_Hypertonie_2004_2Auflage.pdf

  • Bakris GL, Sarafidis PA, Weir MR, Dahlöf B et al. for the ACCOMPLISH Trial investigators (2010): Renal outcomes with diff erent fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecifi ed secondary analysis of a randomised controlled trial. Lancet 375: 1173–1181.

    Article  Google Scholar 

  • Barnett AH, Bain SC, Bouter P, Karlberg B et al (2004): Angiotensin-receptor blockade versus converting–enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351: 1952–1961.

    Article  CAS  PubMed  Google Scholar 

  • Beckett NS, Peters R, Fletcher AE, Staessen JA et al for the HYVET Study Group (2008): Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358: 1887–1898

    Article  CAS  PubMed  Google Scholar 

  • Blood Pressure Lowering Treatment Trialists’ Collaboration (2000): Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356: 1955– 1964.

    Article  Google Scholar 

  • Blood Pressure Lowering Treatment Trialists’ Collaboration (2007): Blood Pressure dependent and independent effects of agents that inhibit the renin-angiotensin system. J. Hypertension 25: 951–958.

    Article  Google Scholar 

  • Brown MJ (2008): Aliskiren. Circulation 118: 773–784.

    Article  CAS  PubMed  Google Scholar 

  • Burgess E, Muirhead N, Rene de Cotret P, Chiu A, et al.; SMART (Supra Maximal Atacand Renal Trial) Investigators (2009): Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol. 20: 893–900.

    Article  CAS  PubMed  Google Scholar 

  • Casas J P, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ (2005): Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366: 2026–2033.

    Article  CAS  PubMed  Google Scholar 

  • Cleland JG, Tendera M, Adamus J, Freemantle et al. (2006): The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 27:2338–2345.

    Article  CAS  PubMed  Google Scholar 

  • Cohn JN, Tognoni G for the Valsartan Heart Failure Trial Investigators (2001): A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667–1675.

    Article  CAS  PubMed  Google Scholar 

  • CONSENSUS Trial Study Group (1987): Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429–1435.

    Article  Google Scholar 

  • Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U et al for The LIFE Study Group (2002): Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995–1003.

    Article  PubMed  Google Scholar 

  • Dahlöf B, Sever PS, Neil R, Poulter N P, Wedel H (2005): Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366: 895–906.

    Article  PubMed  Google Scholar 

  • Davis BD, Piller LB, Cutler JA, Curt Furberg C et al. (2006): Role of Diuretics in the Prevention of Heart Failure. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation 113: 2201–2210.

    Article  CAS  PubMed  Google Scholar 

  • Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group (2002): Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 360: 752–60.

    Article  CAS  PubMed  Google Scholar 

  • Elliott WJ, Meyer PM (2007): Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369: 201–207

    Article  CAS  PubMed  Google Scholar 

  • Flather MD, Yusuf S, Kober L, Pfeffer M et al (2000): Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355: 1575–1581.

    Article  CAS  PubMed  Google Scholar 

  • GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG et al (2009): Val-sartan for prevention of recurrent atrial fibrillation.N Engl J Med. 360: 1606–17.

    Article  PubMed  Google Scholar 

  • Granger CB, McMurray JJV, Yusuf S, Held P et al (2003): Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362: 772–776.

    Article  CAS  PubMed  Google Scholar 

  • Grimm RH, Davis BR, Piller LB, Cutler JA, et al. ALLHAT Collaborative Research Group.(2009): Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome? J Clin Hypertens (Greenwich).11: 466–474.

    Article  CAS  Google Scholar 

  • Heerspink HL, de Zeeuw D (2010): Composite renal endpoints: was ACCOMPLISH accomplished? Lancet 375: 1140–1142.

    Article  PubMed  Google Scholar 

  • Jamerson K, Weber MA, Bakris GL, Dahlöf B, et.al. ACCOMPLISH Trial Investigators (2008): Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 359: 2417–2428.

    Article  CAS  PubMed  Google Scholar 

  • Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group (2004): Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363: 2022–2031.

    Article  CAS  PubMed  Google Scholar 

  • Julius S, Nesbitt SD, Egan BM. for the Trial of Preventing Hypertension (TROPHY) Study Investigators (2006): Feasibility of treating prehypertension with an angiotensinreceptor blocker. N Engl J Med. 354: 1685–1697.

    Article  CAS  PubMed  Google Scholar 

  • Kassenärztliche Bundesvereinigung (2008): Wirkstoff aktuell. Aliskiren (Rasilez®). Internet: www.kbv.de/publikationen/116.html

  • Kizer JR, Dahlöf B, Kjeldsen SE, Julius S et al. (2005): Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol. The Losartan Intervention For Endpoint Reduction in Hypertension Study. Hypertension 45: 46–52.

    CAS  PubMed  Google Scholar 

  • Kunz R, Friedrich C, Wolbers M, Mann JFE (2008): Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin–angiotensin system on proteinuria in renal disease. Ann Intern Med 148:30–48.

    PubMed  Google Scholar 

  • Laverman GD, Navis G, Henning RH, de Jong D, de Zeeuw D (2002): Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 62: 1020–1025.

    Article  CAS  PubMed  Google Scholar 

  • Levy BI (2004): Can angiotensin II Type 2 receptors have deleterious effects in cardiovascular disease? Circulation 109: 8–13.

    Article  PubMed  Google Scholar 

  • Lewis EJ, Hunsicker LG, Bain R P, Rohde RD for the Collaborative Study Group (1993): The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456–1462.

    Article  CAS  PubMed  Google Scholar 

  • Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al for the SCOPE Study Group (2003): The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21: 875–886.

    Article  CAS  PubMed  Google Scholar 

  • Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, Middeke M, Motz W, Lübcke C, Gansz A, Brokamp L, Schmieder RE, Trenkwalder P, Haller H, Dominiak P; PHARAO study group (2008): The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with highnormal blood pressure – a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 26: 1487–1496.

    Article  PubMed  Google Scholar 

  • Malacco E, Santonastaso M, Vari NA, Gargiulo A, Spagnuolo V, Bertocchi F, Palatini P; Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisino-pril Study (2004): Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther 26: 855–865.

    Article  CAS  PubMed  Google Scholar 

  • Mann JF, Ritz E, Kunz R (2006): Renoprotective effects of renin-angiotensin-system inhibitors. Lancet 367: 900.

    Article  PubMed  Google Scholar 

  • Mann JFE, Schmieder RE, McQueen M, Dyal L et al. on behalf of the ONTARGET investigators (2008): Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, doubleblind, controlled trial. Lancet 372: 547–553.

    Article  CAS  PubMed  Google Scholar 

  • Maschio G, Albert D, Ganin G, Locatelli F, Mann JFE et al (1996): Effect of the angio-tensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334: 939–945.

    Article  CAS  PubMed  Google Scholar 

  • Massie BM, Carson PE, McMurray JJ, Komajda M, et al. I-PRESERVE Investigators (2008): Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 359: 2456–2467.

    Article  CAS  PubMed  Google Scholar 

  • McMurray JJV, Östergren J, Swedberg K, Granger CB et al (2003): Effects of candes-artan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362: 767–771.

    Article  CAS  PubMed  Google Scholar 

  • Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME (2000): Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan And Lisinopril Microalbuminuria (CALM) Study. Brit Med J 321: 1440–1444.

    Article  CAS  PubMed  Google Scholar 

  • National Collaborating Centre for Chronic Conditions (2006): Hypertension: management of hypertension in adults in primary care: partial update. London: Royal College of Physicians. Internet: http://guidance.nice. org.uk/CG34/guidance/pdf/ English

  • Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators (2008): Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358: 2433–2446.

    Article  CAS  PubMed  Google Scholar 

  • Peitz GJ, Malesker MA, Sojka SG (2009): Aliskiren-Induced QT Interval Prolongation. Southern Medical Journal. 102: 411–412.

    PubMed  Google Scholar 

  • Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau J-L et al for the Valsartan in Acute Myocardial Infarction Trial Investigators (2003a): Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893–1906.

    Article  CAS  Google Scholar 

  • Pfeffer MA, Swedberg K, Granger CB, Held P et al (2003b): Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362: 559–766.

    Google Scholar 

  • Pitt B, Poole-Wilson PA, Segal R, Martinez FA et al (2000): Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet 355: 1582–1587.

    Article  CAS  PubMed  Google Scholar 

  • Pitt B (2004): ACE inhibitors for patients with vascular disease without left ventricular dysfunction – may they rest in PEACE? N Engl J Med 351: 2115–2117.

    Article  CAS  PubMed  Google Scholar 

  • PROGRESS Collaborative Group (2001): Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033–1041.

    Article  Google Scholar 

  • Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP et al for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators (2004): Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351: 1941–1951.

    Article  CAS  PubMed  Google Scholar 

  • Saunders E, Weir MR, Kong B W, Hollifield J, Gray J, Vertes V et al (1990): A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 150: 1707–1713.

    Article  CAS  PubMed  Google Scholar 

  • Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C (2005): Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol. 16: 3038–3045.

    Article  CAS  PubMed  Google Scholar 

  • Schmieder RE, Hilgers KF, Schlaich M P, Schmidt MW (2007): Renin-angiotensin system and cardiovascular risk. Lancet 369: 1208–1219.

    Article  CAS  PubMed  Google Scholar 

  • Schrader J, Lüders S, Kulschewski A, Hammersen F et al. for the MOSES Study Group (2005): Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Principal results of a prospective randomized controlled study (MOSES). Stroke 36: 1218–1226.

    Article  CAS  PubMed  Google Scholar 

  • Scottish Medicines Consortium (2009): Aliskiren, 150mg and 300mg film-coated tablets (Rasilez®) No. (462/08), Novartis Pharmaceuticals UK Ltd. Internet: www.scottishmedicines.org.uk/smc/files/aliskiren%20(Rasilez)%20FINAL%20DEC%2008%20for%20website.pdf

  • Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC (2010): Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010 Jun 11. [Epub ahead of print]

    Google Scholar 

  • Svensson P, de Faire U, Sleight P, Yusuf S, Jan Östergren J (2001): Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension 38: e28–e32.

    CAS  Google Scholar 

  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002): Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997.

    Article  Google Scholar 

  • The DREAM Trial Investigators (2006): Effect of ramipril on the incidence of diabetes. N Engl J Med 355: 1551–1562.

    Article  Google Scholar 

  • The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators (2003): Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, doubleblind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362: 782–788.

    Article  Google Scholar 

  • The GISEN Group (1997): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857–1863.

    Article  Google Scholar 

  • The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000): Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342: 145–153.

    Article  Google Scholar 

  • The Indian Polycap Study (TIPS) (2009): Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 373: 1341–1351.

    Google Scholar 

  • The ONTARGET Investigators (2008): Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 358: 1547–1559.

    Article  Google Scholar 

  • The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators (2008): Effects of the angio-tensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372: 1174–1183.

    Article  Google Scholar 

  • Verma S, Strauss M (2004): Angiotensin receptor blockers and myocardial infarction. These drugs may increase myocardial infarction – and patients may need to be told. BMJ 329: 1248–1249.

    Article  PubMed  Google Scholar 

  • Wachtell K, Hornestam B, Lehto M, Slotwiner DJ et al (2005a): Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 45:705–711.

    Article  Google Scholar 

  • Wachtell K, Lehto M, Gerdts E, Olsen MH et al (2005b): Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to ate- nolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 45:712–719.

    Article  CAS  Google Scholar 

  • Wald NJ, Law MR (2003) A strategy to reduce cardiovascular disease by more than 80%. BMJ 326: 1419–24.

    Article  CAS  PubMed  Google Scholar 

  • White HD (2003): Commentary. Candesartan and heart failure: the allure of CHARM. Lancet 362: 754–755.

    Article  PubMed  Google Scholar 

  • Wing LMH, Reid MC, Ryan P, Beilin LJ et al for the Second Australian National Blood Pressure Study Group (2003): A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348: 583–592.

    Article  CAS  PubMed  Google Scholar 

  • Yusuf S (2002): From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 89 (2A): 18A–25A.

    Article  PubMed  Google Scholar 

  • Yusuf S, Pfeffer MA, Swedberg K, Granger CB et al (2003): Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362: 777–781.

    Article  CAS  PubMed  Google Scholar 

  • Yusuf S, Diener HC, Sacco RL, Cotton D, Ôunpuu S for the PRoFESS Study Group (2008): Telmisartan to prevent recurrent stroke and cardiovascular Events. N Engl J Med 359:1225–1237.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Friedrich-Plettke-Weg 12, 27570, Bremerhaven

    Prof. Dr. med. Manfred Anlauf

Authors
  1. Prof. Dr. med. Manfred Anlauf
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK Schleswig-Holstein, Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Anlauf, M. (2010). Hemmstoffe des Renin-Angiotensin-Systems. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2010. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-13380-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-13380-0_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-13379-4

  • Online ISBN: 978-3-642-13380-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation